On June 5th, Geelong increased against the trend. Bailitianheng (688506.SH) rose by 5.84% and reached a new historical high price of 209.1 yuan, with a total market value of nearly 82 billion yuan. Recently, the phase III clinical trial of the innovative biological drug injection BL-B01D1 (EGFR × HER3-ADC) independently developed by the company has completed the enrollment of the first subject, who had previously failed to respond to PD-1/PD-L1 monoclonal antibody treatment and platinum-containing chemotherapy for locally advanced or metastatic EGFR wild-type non-small cell lung cancer. In addition, the phase III clinical trial of BL-M07D1, an injection for locally advanced or metastatic HER2-positive breast cancer, was completed with the enrollment of the first subject at the end of May.
A股异动 | 多款产品迎来进展 百利天恒再创新高 市值近820亿元
A-share volatility: Multiple products make progress, Baoli Tianheng hits a new high again, with a market cap of nearly 82 billion yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.